Today the U.S. Food and Drug Administration permitted marketing of a new diagnostic test to aid in detecting a type of herpes virus called cytomegalovirus (CMV) in newborns less than 21 days of age. “Although most people who become infected with cytomegalovirus face little to no risk of serious illness, …
Tag Archives: cytomegalovirus
December, 2018
January, 2018
-
22 January
Astellas and Vical’s Investigational Cytomegalovirus Vaccine Fails in Late-Stage Trial in Hematopoietic Stem Cell Transplant Recipients
TOKYO and SAN DIEGO, Jan. 22, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ: VICL) announced today that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant (HSCT) recipients, did not meet its primary or …
November, 2017
-
9 November
FDA Approves Merck’s Prevymis for Prevention of Cytomegalovirus Infection in HSCT Patients
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS™ (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) …
April, 2017
-
14 April
Glioblastoma Patients May Benefit from a Vaccine-Chemotherapy Combination
Bottom Line: A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research. Author: Lead …
February, 2017
-
27 February
Merck’s Letermovir Demonstrates Positive Results in Late-Stage CMV Study
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an …
December, 2016
-
16 December
Herpes Virus Linked to Most Common Type of Childhood Cancer
(WASHINGTON, December 15, 2016) — Newborns with congenital cytomegalovirus (CMV) — a common virus in the herpes family — may have an increased risk of developing acute lymphocytic leukemia (ALL), according to new research published online today in Blood, the Journal of the American Society of Hematology (ASH). The study suggests the …
October, 2016
-
19 October
Merck’s Antiviral Drug Letermovir Meets Primary Endpoint in Late-Stage Trial
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. The global, multicenter, randomized, placebo-controlled study evaluated the efficacy and safety of letermovir for …
December, 2015
-
28 December
Chimerix’s Lead Candidate Misses Primary Endpoint in Late-Stage Study
DURHAM, N.C., Dec. 28, 2015 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention …